Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $36.31, for a total value of $7,262,000.00. Following the sale, the chief executive officer owned 999,154 shares of the company’s stock, valued at approximately $36,279,281.74. The trade was a 16.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eric Venker also recently made the following trade(s):

• On Wednesday, October 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $36.59, for a total value of $7,318,000.00.
• On Tuesday, October 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $35.11, for a total value of $7,022,000.00.
• On Wednesday, September 30th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $36.62, for a total value of $7,324,000.00.
• On Friday, August 28th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $35.77, for a total value of $7,154,000.00.

Roivant Sciences Price Performance

ROIV traded down $1.61 on Thursday, hitting $36.62. 10,177,004 shares of the stock were exchanged, compared to its average volume of 6,489,550. Roivant Sciences Ltd. has a 12 month low of $19.79 and a 12 month high of $42.50. The business has a 50-day moving average of $36.67 and a two-hundred day moving average of $31.66. The firm has a market capitalization of $26.45 billion, a price-to-earnings ratio of -69.09 and a beta of 1.23.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The firm had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. Equities research analysts expect that Roivant Sciences Ltd. will post -2.00 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Assenagon Asset Management S.A. grew its holdings in shares of Roivant Sciences by 18.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock valued at $295,965,000 after purchasing an additional 1,286,464 shares during the last quarter. Perceptive Advisors LLC increased its position in Roivant Sciences by 3.8% during the 1st quarter. Perceptive Advisors LLC now owns 8,285,461 shares of the company’s stock worth $229,507,000 after purchasing an additional 300,000 shares in the last quarter. Pictet Asset Management Holding SA lifted its stake in Roivant Sciences by 20.3% in the 3rd quarter. Pictet Asset Management Holding SA now owns 4,173,123 shares of the company’s stock valued at $152,597,000 after purchasing an additional 704,783 shares during the last quarter. Bank of America Corp DE lifted its stake in Roivant Sciences by 8.0% in the 1st quarter. Bank of America Corp DE now owns 3,163,821 shares of the company’s stock valued at $87,638,000 after purchasing an additional 235,493 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Roivant Sciences by 6.1% in the 1st quarter. Janus Henderson Group PLC now owns 3,095,448 shares of the company’s stock valued at $85,790,000 after purchasing an additional 177,339 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ROIV shares. Citigroup upped their price target on shares of Roivant Sciences from $46.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a research note on Friday, July 31st. Jefferies Financial Group boosted their price objective on shares of Roivant Sciences from $42.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Finally, Guggenheim raised their target price on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Roivant Sciences currently has an average rating of “Moderate Buy” and an average price target of $46.55.

Roivant Sciences Company Profile

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.